Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamolenic acid - Scotia Pharmaceuticals

Drug Profile

Gamolenic acid - Scotia Pharmaceuticals

Alternative Names: Efamast; Efarmol; Epogam; Epogam Snip-Off capsules; Epostart; Gamma linolenic acid; Gamolenic acid/vitamin E; Primast; Primogam

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scotia Holdings [CEASED]; Scotia Pharmaceuticals [CEASED]
  • Class Small molecules; Unsaturated fatty acids
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunomodulators; Prostaglandin synthase stimulants; Thromboxane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis
  • Market Withdrawal Breast pain
  • Discontinued Breast cancer; Rheumatoid arthritis

Most Recent Events

  • 27 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 07 Oct 2002 The UK Medicines Control Agency has withdrawn the marketing authorisations for Evening primrose oil for atopic dermatitis (as Epogam) and mastalgia (as Efamast) in the UK
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top